“Cancer is an enormous problem in this part of the world, and does not discriminate between race, economic status, age, or sex. Many of our patients either fail standard therapy or have cancers where there is no effective therapy if unresectable. We owe it to our patients to develop better treatment for them. With the return of several well trained staff from leading institutions overseas, the National University Hospital and National University of Singapore have been most privileged to have the National Cancer Centre Singapore, Johns Hopkins Singapore, Chinese University of Hong Kong, National Taiwan University Hospital, Sir Charles Gairdner Hospital, and the Yonsei Cancer Centre join us in our pursuit of better treatment for our patients.
We also believe that there is a tremendous opportunity to contribute to science with our collaboration. We will be able to simultaneously test new therapies in Asians and Caucasians prospectively to answer whether there is a difference in the biology of cancer in different ethnic groups, as well as examine differences, if any, in drug metabolism in different populations. This information will be of significant interest to the pharmaceutical industry, and the CTRG hopes to play a major role in the development of the Life Science industry in the Asia-Pacific region.”
Since 1997, The CTRG has rapidly established itself and is now recognized as the leading group for evaluating new therapeutic strategies in the Asia-Pacific region. The CTRG has built up an impressive infrastructure, presented a number of studies at cancer meetings, and have published a number of peer-reviewed papers in high impact journals.
We position ourselves as a major centre for early phase drug development in clinical trials with expertise in genomics and proteomics research. The Group is well-recognized by the international academic community and industry, as well as the United States National Cancer Institute (NCI) and Mayo Clinic through various collaborative studies. These project collaborations have enabled cancer patients in Asia-Pacific to benefit greatly.
It remains the aim of CTRG to contribute to the advancement towards better treatments in cancer.
Professor John Eu-Li WongNational University Health SystemFounder of the Cancer Therapeutics Research Group (CTRG)
Joint Management Committee
For more information on CTRG and regional clinical trials, please contact Ms. Vilianty at +65 6772 4619 or email firstname.lastname@example.org.